Treosulfan

Treosulfan is a bifunctional alkylating agent. It also has activity in ovarian cancer and other solid tumor types. (In Vitro) :Treosulfan is an alkylating agent. Treosulfan inhibits several cancer cell lines, such as Panc-1, Miapaca-2 and Capan-2 cells, with IC50s of 3.6 μg/mL, 1.8 μg/mL and 2.1 μg/mL respectively, and shows nearly 100% cytotoxicity on these cell lines at 100 μg/mL. Treosulfan (0.1-100 μg/mL) in combination with LY 188011 exhibits enhanced activity against cancer cells. However, Treosulfan (1, 2.5, 5 μg/ml) combined with 5-FU (0.1, 0.25, 0.5 μg/ml) has antagonistic effect on Panc-1 cells at intermediate and high concentrations, and on Miapaca-2 cells at all doses. Treosulfan (800 μg/mL) dramatically reduces erythrocyte forward scatter, increases the percentage of annexin-V-binding cells, [Ca2+]i, and ROS. Removal of extracellular Ca2+ abrogates the effect of Treosulfan on annexin-V-binding. (In Vivo) :Treosulfan (1.5 g/kg/day) induces a rapid myeloablation, depletes the splenic B and T cells in mice. Treosulfan (1.5 g/kg/day) causes olny interleukin-2 production in spleen cells for a short time and without obvious significant effect on synthesis of tumor necrosis factor-α and/or IFN-γ in mice.

299-75-2

NSC 39069 | Treosulphan

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO:100 mg/mL (359.32 mM) ; H2O:50 mg/mL (179.66 mM; Need ultrasonic)

CS (=O) (=O) OC[C@@H] ([C@H] (COS (=O) (=O) C) O) O

C6H14O8S2

278.3

Storage temperature: -20°C. Stability: ≥ 2 years